Search Results

The AChRAb Assay is a radioimmunoassay for the in-vitro-diagnostic semiquantitative determination of autoantibodies against the acetylcholine receptor in human serum.

The AChRAb assay is useful as an aid in the differential diagnosis of Myasthenia Gravis (MG) in conjunction with other clinical and laboratory findings.

Not Found

This document is an FDA 510(k) clearance letter for an in vitro diagnostic device, not an AI/ML medical device. Therefore, it does not contain the specific information requested about acceptance criteria, study designs with test and training sets, expert adjudication, or comparative effectiveness studies for AI.

This document confirms the substantial equivalence of the "AChRAb Acetylcholine Receptor Ab Kit" to a legally marketed predicate device. The indications for use state it is a radioimmunoassay for the in-vitro-diagnostic semiquantitative determination of autoantibodies against the acetylcholine receptor in human serum, useful as an aid in the differential diagnosis of Myasthenia Gravis (MG) in conjunction with other clinical and laboratory findings.

Due to the nature of this document (an FDA 510(k) clearance for an in vitro diagnostic kit, not an AI/ML device), the requested information about acceptance criteria and the study proving the device meets those criteria, as typically described for AI/ML devices, cannot be fully provided from the given text.

However, I can extract what is implicitly present and acknowledge what is missing based on the typical requirements for such devices:

1. Table of Acceptance Criteria and Reported Device Performance:

This document does not explicitly state quantitative acceptance criteria or detailed device performance results in a table format. For an in vitro diagnostic kit like this, performance is typically demonstrated through analytical and clinical performance studies, often including data on sensitivity, specificity, precision, accuracy, and linearity. These results would be compared against predefined criteria for the assay to be considered acceptable. The 510(k) clearance implies that such studies were submitted and found acceptable by the FDA, but the details are not included in this letter.

2. Sample Size for Test Set and Data Provenance:

Not specified in the provided text. For an IVD kit, this would typically involve various cohorts including healthy individuals and patients with the target condition (Myasthenia Gravis) and possibly other relevant conditions.

3. Number of Experts and Qualifications for Ground Truth:

Not specified in the provided text. For diagnostic kits, ground truth for clinical performance can be established by established clinical diagnosis (e.g., based on clinical presentation, other diagnostic tests, and expert medical opinion), but there's no mention of specific experts establishing ground truth for a test set in the AI/ML sense.

4. Adjudication Method:

Not applicable or specified in the provided text. Adjudication methods like 2+1 or 3+1 are typically for reconciling discrepancies in expert annotations for AI ground truth, which is not the context here.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

Not applicable. This is not an AI/ML device, so there would be no effect size of human readers improving with AI vs. without AI assistance.

6. Standalone Performance Study:

Since this is an in vitro diagnostic kit, its performance is inherently "standalone" in the sense that the kit itself provides the measurement. The clinical performance studies would demonstrate its performance in isolating the target analyte and providing accurate results against a clinical diagnosis. However, this is not a "standalone algorithm performance" in the AI/ML context.

7. Type of Ground Truth Used:

While not explicitly stated for a "test set" in the AI/ML context, the clinical utility of an in vitro diagnostic assay like the AChRAb kit would be evaluated against a clinical diagnosis of Myasthenia Gravis, which is established by a combination of clinical symptoms, neurological examination, and other diagnostic tests.

8. Sample Size for Training Set:

Not applicable. This is not an AI/ML device, so there is no concept of a "training set" in the machine learning sense. The assay itself is a biochemical test.

9. How Ground Truth for Training Set was Established:

Not applicable as there is no training set in the AI/ML context. The development of an IVD assay involves extensive research and development to optimize the assay components and parameters (e.g., antibody concentrations, incubation times, cutoff values) to achieve optimal performance, but this is a different process from establishing ground truth for machine learning training data.

Ask a specific question about this device

The KRONUS Blocking AChRAb RIA Assay Kit is for the semi-quantitative determination of blocking antibodies to the acetylcholine receptor in human serum. The KRONUS Blocking AChRAb Assay is useful as an aid in the diagnosis of myasthenia gravis (MG).

Not Found

The provided text is an FDA 510(k) clearance letter for the KRONUS I123 Acetylcholine Receptor Blocking Antibody Kit (KRONUS Blocking AChRAb RIA Assay Kit). This document focuses on the regulatory approval process and includes the device’s indications for use. It does not contain any information about acceptance criteria, device performance studies, sample sizes, expert qualifications, or ground truth establishment.

Therefore, I cannot provide the requested table and information based directly on the given text.

The information you are requesting, such as acceptance criteria and detailed study results, would typically be found in the manufacturer's 510(k) submission document itself, or potentially in a more comprehensive summary document provided by the FDA, but not in the clearance letter.

Ask a specific question about this device

The IBL Acetylcholine Receptor Antibody (ARAb) Radio Receptor Assay is for the in-vitrodiagnostic semi-quantitative determination of autoantibodies against the acetylcholine receptor in human serum and plasma.

The ARAb Assay kit is useful as an aid in the differential diagnosis of Myasthenia Gravis (MG).

Not Found

The provided document is a 510(k) premarket notification letter from the FDA to IBL-Hamburg GmbH regarding their IBL ARAb RRA Test Kit. This document formally approves the marketing of the device, stating it is substantially equivalent to legally marketed predicate devices. However, the document does not contain the detailed study information, acceptance criteria, or performance data that would be required to answer the prompt.

Therefore, I cannot fulfill the request for a table of acceptance criteria, device performance, sample sizes, ground truth establishment methods, expert qualifications, adjudication methods, or MRMC study details based only on the provided text.

The document primarily focuses on the regulatory aspects of the FDA's decision, such as:

• Device Name: IBL ARAb RRA Test Kit
• Regulation Number: 21 CFR 866.5660
• Regulation Name: Multiple autoantibodies immunological test system
• Regulatory Class: Class II
• Product Code: NST
• Indications For Use: The IBL Acetylcholine Receptor Antibody (ARAb) Radio Receptor Assay is for the in-vitro diagnostic semi-quantitative determination of autoantibodies against the acetylcholine receptor in human serum and plasma. The ARAb Assay kit is useful as an aid in the differential diagnosis of Myasthenia Gravis (MG).

To provide the requested information, the actual 510(k) submission document, particularly the sections detailing the analytical and clinical performance studies, would be necessary.

Ask a specific question about this device

The KRONUS Acetylcholine Receptor Antibody (AChRAb) Assay Kit is for the quantitative or qualitative determination of acetylcholine receptor antibody in human serum. The KRONUS Acetylcholine Receptor Antibody(AChRAb) kit is useful as an aid in the differential diagnosis of Myasthenia Gravis.

Not Found

The provided K042248 document is a 510(k) clearance letter from the FDA for the Kronus I125 Acetylcholine Receptor Antibody Kit. This document does not contain the detailed study information, acceptance criteria, or performance data that would be used to prove the device meets acceptance criteria.

FDA 510(k) clearance letters primarily state that the device is substantially equivalent to a legally marketed predicate device and outline the regulatory classification and general controls. They typically do not include the raw data, study design, or performance metrics from the studies submitted in the 510(k) application itself.

Therefore, based solely on the provided text, I cannot extract the information required to populate the requested table and answer the study-related questions.

To answer your request, I would need access to the full 510(k) submission document or a summary of the performance data that was provided to the FDA by Kronus Market Development Associates.

Ask a specific question about this device